A new study published in Arteriosclerosis, Thrombosis, and Vascular Biology finds that evinacumab, a monthly IV drug, can cut LDL cholesterol by 50% in children and adults with homozygous familial hypercholesterolemia (HoFH). It offers hope for those who don't respond well to standard treatments like statins and PCSK9 inhibitors.